DDC Overview
Molecule Name
Aromatic-L-amino-acid decarboxylase
Synonyms
Aromatic-L-amino-acid decarboxylase,Dopa decarboxilase,AADC
Drug Development Progress
Drugs in Clinical Trials12
Approved Drugs8
Highest Development StageApproved
Target Synonym
EC:4.1.1.28，EC 4.1.1，DDC，AADC，Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase)，Aromatic-L-Amino-Acid Decarboxylase，Aromatic L-Amino Acid Decarboxylase，EC 4.1.1.28，DOPA decarboxylase
Background
Dopa decarboxilase (DDC), also known as aromatic amino acid decarboxylase, is a group II decarboxylase. The enzyme catalyzes the decarboxylation of aromatic L-amino acids to produce the corresponding amines. DDC produces the neurotransmitters dopamine and serotonin from L-Dopa and L-5-hydroxytryptophan, respectively. DDC inhibitors is in clinical use to treat Parkinson's disease(PD), usually co-administrated with L-DOPA. DDC would block peripheral conversion to dopamine and allow a greater percentage of L-DOPA to reach the brain, causing an increase in brain dopamine levels, and reducing the side effects of dopamine-rich blood.
DDC Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| VGN-R09 | VGN-R09b; VGN-R09 | Phase 3 Clinical | Shanghai Vitalgen BioPharma Co Ltd | Aromatic amino acid decarboxylase deficiency; Parkinson Disease | Details |
| Levodopa/Carbidopa (Hengrui Medicine) | HRG-2010 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Parkinson Disease | Details |
| Buspirone/Carbidopa/Levodopa | Phase 2 Clinical | Universite Laval | Multiple Sclerosis; Spinal Cord Injuries | Details | |
| Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical) | WD-1905 | Phase 2 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
| Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical) | WD-1603 | Phase 2 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinson Disease; Parkinsonian Disorders | Details |
| Ezaladcigene resoparvovec | VY-AADC; VY-AADC01; GZ-404477; AV-201; VY-AADC02 | Phase 1 Clinical | University Of California, Voyager Therapeutics Inc | Aromatic amino acid decarboxylase deficiency; Parkinson Disease | Details |
| AAV2-hAADC gene therapy (UCSF) | Phase 1 Clinical | University Of California San Francisco | Details | ||
| Levodopa/Carbidopa (Contera Pharma) | JM-012; CP-012; SOL-707 | Phase 1 Clinical | Contera Pharma | Parkinson Disease | Details |
| RGL-193 | RGL-193 | Phase 1 Clinical | Shanghai Regenelead Therapies Co Ltd | Parkinson Disease | Details |
| Carbidopa/oxytriptan | EVX-101 | Phase 1 Clinical | Evecxia Therapeutics Inc | Depression; Depressive Disorder | Details |
| Levodopa/Carbidopa granule(WD Pharmaceutical) | WD-2010 | Phase 1 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
| Levodopa/Carbidopa(WD Pharmaceutical) | WD-1804 | Phase 1 Clinical | Shanghai WD Pharmaceutical Co Ltd | Parkinsonian Disorders | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Levodopa/Benserazide Hydrochloride | Approved | F. Hoffmann-La Roche Ltd | Madopar | Switzerland | Parkinson Disease | F. Hoffmann-La Roche Ltd | 1973-06-27 | Parkinson Disease | Details | |
| Eladocagene exuparvovec | PTC-AADC | Approved | National Taiwan University, Ptc Therapeutics Inc | KEBILIDI, Upstaza | EU | Amino Acid Metabolism, Inborn Errors | Ptc Therapeutics International Ltd | 2022-07-18 | Amino Acid Metabolism, Inborn Errors; Aromatic amino acid decarboxylase deficiency | Details |
| Levodopa/Carbidopa | DM-1992; AP-CDLD; TPI-926; ND-0612H; PW-4153; LCIG; ABT-SLV187; IPX-203; INP-107(POD™ carbidopa/levodopa); IPX-066; ABT-SLV-187; AP-09004; AP-CD/LD; ND-0612; ND-0680; ND-0612L; IPX-054 | Approved | Merck Sharp & Dohme Corp | Patrome, DopaFuse, Sinemet, Numient, Menesit, Duodopa, Vadova, Rytary, Isicom, Duopa, Flexilev, CREXONT, Nacom (imciromab), Nacom retard, Parcopa | United States | Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary | Organon | 1975-05-02 | Albinism; Albinism, Oculocutaneous; Amblyopia; Amyotrophic Lateral Sclerosis; Aphasia, Broca; Cocaine-Related Disorders; Cognition Disorders; Depressive Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Diabetes Mellitus; Diabetic Retinopathy; Gait Apraxia; Motor Neuron Disease; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Parkinsonian Disorders; Stroke | Details |
| Benserazide Hydrochloride | Ro-4-4602 | Approved | Mainland China | Parkinson Disease; Dyskinesias | Shanghai Yishengyuan Pharmaceutical Co Ltd | 1995-01-01 | Anemia, Sickle Cell; beta-Thalassemia; Dyskinesias; Parkinson Disease | Details | ||
| Foslevodopa/Foscarbidopa | ABBV-951 | Approved | Abbvie Inc | VYALEV, Vyalev, Produodopa | Romania, Cyprus, Belgium | Parkinson Disease | Abbvie Deutschland Gmbh & Co Kg, Abbvie Inc, Abbvie Sa | Parkinson Disease | Details | |
| Carbidopa/Entacapone/Levodopa | ELC-200; ODM-101 | Approved | Orion Pharma | Stalevo, LECIGon, Trigel, LECIGel, 达灵复 | United States | Parkinson Disease | Orion Pharma A/S | 2003-06-11 | Parkinson Disease | Details |
| Carbidopa | MK-486 | Approved | Lodosyn | United States | Parkinson Disease | Aton | 1977-04-25 | Orthostatic Intolerance; Parkinson Disease; Postural Orthostatic Tachycardia Syndrome | Details | |
| Carbidopa/Melevodopa | V-1512; GT-1512; CHF-1512; CNP-1512 | Approved | Chiesi Farmaceutici SPA | Sirio | Italy | Parkinson Disease | null | 2003-01-01 | Parkinson Disease | Details |